US Biobanks Marke 2025 – 2034

As per the US Biobanks Market analysis conducted by the CMI team, the US biobanks market is expected to record a CAGR of 7.23% from 2025 to 2034. In 2025, the market size was USD 19.67 Billion. By 2034, the valuation is anticipated to reach USD 37.03 Billion.

Overview

Biobanks are reported to notably shorten the research timelines by providing direct access to the ready-to-use biological materials for clinical and preclinical studies. This access does eliminate the cost and time involved in new sample collection and also allows for the initiation of rapid study. With biopharma companies increasingly pursuing adaptive clinical trial designs and personalized therapies, the biobanks’ strategic value in acceleration of development cycles, improvement of trial design, and enhancement of regulatory compliance does continue to grow. As a consequence, partnerships between industry stakeholders and biobanks are expanding, thereby embedding biobanks into the drug development value chain.

As per the ClinicalTrials.gov report (dated May 13, 2025), interventional trials comprise the majority of clinical studies in the US, thereby indicating a robust industry focus on the evaluation of the safety and efficacy of the new treatments via active testing. It further states that observational studies, on the contrary, do represent a smaller fraction, thereby highlighting preference for proactive trial designs supporting commercialization strategies and regulatory submissions.

Key Trends & Drivers

• Initiative of Collaborative Research

Numerous stakeholders do combine their knowledge, resources, samples, and data in collaborative biobanking research projects for answering some research objectives/questions. Researchers would find a chance to access more varied and a broader spectrum of samples due to the collaborative methods, which, in turn, are likely to generate widely applicable and more reliable results.

The participants could thus provide the other participants (who are part of this initiative) access to their collections of biobanks, inclusive of data and samples. As an outcome, the researchers have access to a greater number of samples than they could gather by themselves. Governance structures are implemented in the collaborative ventures for supervising data sharing, guaranteeing adherence to the ethical regulations and principles, and handling matters pertaining to data permission, privacy, and ownership.

• Increased Focus on Population Genomics Programs and Precision Medicine

The rising focus on population genomics programs and precision medicine is amongst the prominent drivers of the US biobanks market. The transformation is basically being fueled by improved data analytics, the convergence of cutting-edge genomic technologies, and a shift toward more customized healthcare approaches.

Precision medicine does aim to customize treatments on the basis of individual genetic profiles, thereby facilitating targeted and more effective therapies. Population genomics does emphasize understanding the genetic diversity within a wider population, finally paving the way for more accurate interventions following diagnostics.

With drug development and medical research getting more personalized, the need for genetic biomarkers predicting individual responses to the therapies has witnessed an upsurge. Biobanks are playing an important role herein by storing as well as providing access to the biological samples rich in genetic data. On these grounds, Amgen has leveraged the biobank resources for identifying genetic biomarkers pertaining to response to its drugs.

What’s trending in the US Biobanks Market?

Equipment like cryogenic freezers, liquid nitrogen tanks, and automated storage systems are necessary for long-term preservation meant for future research. Plus, with robotics and automation increasingly adopted within biobanks, high-performance equipment designed for efficiency, scalability, and precision is witnessing an increase in demand. The US is the focal point of large-scale genomic studies like the All of Us Research Program, which are into the transformation of personalized medicine with precision healthcare.

What would be Business Impact of the US tariffs on the US Biobanks Market?

US tariffs on the biobanks-related equipment as well as materials are likely to increase the operational costs pertaining to the US biobanks owing to delayed innovation on account of reduced R&D investment, higher import costs, and the market players being compelled to reconfigure the supply chains/find domestic suppliers. On the other hand, tariffs could also create wider economic uncertainty, thereby affecting the investors’ confidence along with the overall fascination of the US regarding clinical trials, as the sponsors based overseas may opt for affordable economies for research.

Key Threats

• Higher Upfront Cost

One of the key restraints witnessed by the US biobanks market is that of higher upfront capital expenses (CapEx) needed for establishing and maintaining biobank facilities. Biobanks, particularly the ones that are aiming to handle huge volumes of biological samples for precision medicine, advanced research, or large-scale genomic studies, do need notable investment in equipment, infrastructure, and technology. Such costs could be a barrier to smaller entities and new entrants who are looking to cash in on the rising demand for biobanking services. The automated systems, specialized infrastructure, long-term storage needs, regulatory compliance costs, and ongoing operational overheads do contribute to these restraints.

Opportunities

The growing focus on green lab solutions and sustainability does represent an opportunity to transform the US biobanks market. With the global focus shifting toward energy efficiency amidst responsibility toward the environment, the biobanks sector herein is witnessing an upsurge in sustainable practices. Biobanks, which are capable of managing huge volumes of biological samples, usually need energy-intensive storage solutions. As such, they are under visible pressure for reducing their carbon footprint, minimizing waste, and lowering their energy consumption. Such challenges are now being looked upon as opportunities regarding innovation, thereby driving the discovery of environmentally friendly technologies.

Category Wise Insights

By Product & Services

• Products

Products are holding a significant market share owing to the rise in adoption of automated sample handling systems, advanced storage equipment, and laboratory information management systems (LIMS). Growing demand for the high-throughput biobanking infrastructure and enhanced sample preservation technologies is also catalysing the products’ uptake as biobanks are upscaling operations for meeting increasing needs in precision medicine, genomics, and clinical research.

• Services

The services segment holds the majority of the market share and the status quo is expected to remain unchanged going forward. This could be reasoned with the rise in demand for sample storage after processing and data management solutions amongst the pharmaceutical companies, healthcare providers, and research institutions.

Rise in demand for outsourced biobanking services like genomic analysis, ample logistics, and quality assurance has let organizations emphasize core research while ascertaining operational efficiency and regulatory compliance. Plus, rise in complexity of biospecimen handling along with need for the standardized protocols have propelled adoption of biobank services at the professional level, thereby contributing to the services’ segment’s dominance in the US

By Biospecimen

• Human Tissues

Human tissues held more than 35% of the overall market share in 2024. This could be owing to the critical role played on their part in biomarker discovery, disease modelling, and drug development, especially in regenerative medicine and oncology. The demand for annotated, well-preserved tissue samples has risen as the researchers are increasingly relying on the tissue-based studies for understanding the response of treatment for disease progression. Plus, advancements with respect to imaging technologies and tissue preservation have further improved their utility across commercial and academic research settings.

• Organs

Organs are amongst the critical specimens contributing toward expansion of the US biobanks market. They serve areas such as disease modelling, regenerative medicine, and development of new therapies for conditions that affect specific organs. The rise in demand for well-preserved, high-quality, and annotated organ samples for studies related to the progression of disease and response to treatment, especially in orthopaedics and oncology, is accelerating the growth.

• Stem Cells

The stem cell segment is anticipated to register the quickest CAGR during the forecast period owing to the rise in applications of stem cells in cell-based therapies, regenerative medicine, and personalized treatment approaches. Increased clinical trials that involve stem cell-based interventions coupled with advancements in the cryopreservation techniques are accelerating the demand for stem cells further. Overall, the growing inclination of researchers in stem cells for cardiovascular, neurological, and autoimmune disorders does contribute to the growth of the segment.

By Type

• Physical/Real Biobanks

The physical/real biobanks are holding the highest market share by type. This could be credited to their widespread adoption with regard to managing and storing huge volumes of biospecimens with stringent quality and temperature controls. Such biobanks do extend support to translational research, clinical trials, and drug development by granting access to annotated, well-preserved biological samples. Their regulatory compliance, established infrastructure, and ability to handle diverse specimen types contribute to the dominance further.

• Virtual Biobanks

Virtual biobanks are likely to witness the quickest CAGR owing to the increase in digitalization of healthcare data, the rise in demand for access to samples remotely, and the need for superlative data sharing across the research institutions. They facilitate improved collaboration, centralized data integration, and reduced reliance on the physical infrastructure, thereby rendering them ideal for extending support to real-time analytics, multi-site studies, and scalable biobanking solutions in personalized medicine and genomics.

By Application

• Therapeutics

The therapeutics segment is driven by increased use of the biobanked samples in the development of targeted therapies, personalized treatment approaches, and regenerative medicine. Rising focus on gene and cell therapies coupled with a greater number of stakeholders focusing on translational research also supports rapid expansion of the segment.

• Drug Discovery & Clinical Research

Drug discovery & clinical research facilitate well-characterized biological samples with associated clinical data in order to develop new drugs, identify the biomarkers, and advance precision medicine. The demand does fuel growth of biobanks as they extend support to early-stage research, enable patient stratification, and help with discovery as well as validation of new drug therapies and targets, particularly for chronic and complex diseases.

• Clinical Diagnostics

Clinical diagnostics are expected to witness a sizable CAGR during the forecast period due to the rising use of biobanked samples for biomarker validation, early disease detection, and companion diagnostics. The adoption is further driven by growing demand for data-driven, accurate diagnostic tools in the areas of infectious diseases, oncology, and genetic testing.

How is AI impacting the US Biobanks Market?

AI, by analyzing exhaustive datasets of biobank specimens and clinical information associated with them, identifies new biomarkers and drug targets. This does reduce the cost and time involved in early-stage R&D activity. AI-driven analytics are capable of integrating health and genomic data from biobanks for creating personalized therapeutic strategies. This, in turn, facilitates the researchers in developing targeted treatments and stratifying patients for various clinical trials, which is important for advancing personalized medicine. AI also uses biobank data for building predictive models for progression of disease, response to treatment, and patient outcomes.

Report Scope

Key Developments

The US biobanks market is witnessing a significant organic and inorganic expansion. Some of the key developments include

• In March 2025, LabVantage Solutions, Inc. introduced LabVantage 8.9 – the latest version of its LIMS with the objective of boosting productivity, ensuring compliance and precision, and streamlining complicated workflows.

• In February 2025, Germany-based Merck KGaA began the next level of talks for acquiring SpringWorks Therapeutics (a cancer and rare disease drug maker based in the US).

Leading Players

The US biobanks market is highly competitive, with a large number of service providers globally. Some of the key players in the market include:

• Thermo Fisher Scientific Inc.
• Merck KGaA
• QIAGEN
• Hamilton Company
• Tecan Trading AG
• ViaCord (Revitty)
• Cryo-Cell
• BioCision LLC
• Icbiomedical
• Charles River Laboratories
• Azenta US Inc.
• Stemcell Technologies
• Biovault Family
• LabVantage Solutions Inc.
• Precision Cellular Storage Ltd.
• Others

These firms apply a plethora of strategies to enter the market, including innovations, mergers and acquisitions, and collaboration. The US biobanks market is shaped by the presence of diversified players that compete based on product innovation, vertical integration, and cost efficiency.

The US Biobanks Market is segmented as follows:

By Product & Services

• Products
• Biobanking Equipment
• Temperature Control Systems
• Freezers & Refrigerators
• Cryogenic Storage Systems
• Thawing Equipment
• Incubators & Centrifuges
• Alarms & Monitoring Systems
• Accessories & Other Equipment
• Biobanking Consumables
• Laboratory Information Management Systems
• Services
• Biobanking & Repository
• Lab Processing
• Qualification/Validation
• Cold Chain Logistics

By Biospecimen

• Human Tissues
• Organs
• Stem Cells
• Adult Stem Cells
• Embryonic Stem Cells
• IPS Cells

By Type

• Physical/Real Biobanks
• Tissue Biobanks
• Population-based Biobanks
• Genetic (DNA/RNA)
• Disease-based Biobanks
• Virtual Biobanks

By Application

• Therapeutics
• Drug Discovery & Clinical Research
• Clinical Diagnostics

[embedsocial_reviews id=”d4ae80cffae3d938f997111953699a733c8e6f99″]